Adenosine triphosphate (ATP) and verapamil successfully terminated paroxysmal supraventricular tachycardia in about 90% of infants, compared to 61-71% with digitalis.
Observational
Does adenosine triphosphate or verapamil improve the termination of paroxysmal supraventricular tachycardia compared to digitalis in infants?
ATP and verapamil are highly effective and rapid for terminating PSVT in infants compared to digitalis, making them the preferred drugs of first choice for emergencies.
The treatment of paroxysmal supraventricular tachycardia (PSVT) in infancy with digitalis, adenosine triphosphate (ATP) and verapamil is reported. Treatment was successful in about 90% of the patients treated with ATP and verapamil and in 61--71% of the patients treated with digitalis (Lanatoside C). Verapamil terminated the tachycardia within 2 minutes of administration in most instances and ATP in less than 1 minute. Digitalis, however, took as long as 2 hours; it was therefore excluded as the drug of first choice in emergencies, and is better suited for treating patients with poor hemodynamics. Side effects with ATP are common but short-lived. With verapamil, side effects are rare, but may be serious if certain contraindications are not taken into account. Digitalis in the dose used in this trial rarely produced side effects. We conclude that ATP or verapamil is the drug of first choice for quick termination of PSVT in infancy.
Greco et al. (Wed,) conducted a observational in Paroxysmal supraventricular tachycardia (PSVT). Adenosine triphosphate (ATP) and verapamil vs. Digitalis (Lanatoside C) was evaluated on Successful termination of tachycardia. Adenosine triphosphate (ATP) and verapamil successfully terminated paroxysmal supraventricular tachycardia in about 90% of infants, compared to 61-71% with digitalis.